纳斯达克： -- -- --

最近浏览

实时行情

意见反馈

默沙东

NYSE:MRK 延时15分钟
  • 今开：--
    昨收：--
  • 今日区间：--
    52周区间：--
  • 成交量：--
    成交额：--
  • 市 值：--
    市盈率：--
  • 振幅：
    每股收益：
成交量

董事会

Robert M. Davis
Robert M. Davis is currently the Chairman, President & Chief Executive Officer at Merck & Co., Inc. He is also the President, Chief Executive Officer & Director at MSD Pharma (Singapore) Pte Ltd. Additionally, he holds the position of Chairman at Gambro AB and serves as a Director at Catalyst, Inc., Duke Energy Corp., Project HOPE-The-People-To-People Health Foundation, Inc., and AdvaMedDx. In his former positions, Mr. Davis served as a Director at C. R. Bard, Inc. (New Jersey) from 2015 to 2017. He was the Director-Corporate Financial Planning at Eli Lilly & Co. from 1990 to 2004. From 2004 to 2010, he held the role of Chief Financial Officer & Vice President at Baxter Healthcare Corp. He then became the VP & President-Medical Products Business at Baxter International, Inc. from 2010 to 2014. He also served as a Trustee at Rush University Medical Center. Mr. Davis completed his undergraduate degree at Miami University. He obtained an MBA from Kellogg School of Management. He also holds a graduate degree from Northwestern University School of Law.
Thomas Henry Glocer
Mr. Thomas H. Glocer is a Chairman at Istari Global Ltd., an Executive Chairman at BlueVoyant LLC, a Co-Founder & Partner at Communitas Capital Partners LLC, an Executive Chairman at Capitolis, Inc., an Independent Member-Supervisory Board at Publicis Groupe SA, a Lead Independent Director at Morgan Stanley, a Founding Partner at Angelic Ventures LP, a Member at The American Law Institute, a Member of Supreme Court of the United States, a Lead Independent Director at Merck & Co., Inc., a Member at New York State Bar Association, a Chief Executive Officer at Blueteam Investor LLC, a Member at European Business Leaders' Convention, a Member at The Business Council, a Member-Madison Council of The Library of Congress (District of Columbia) and a Member-Presidents Council International Activities at Yale University. He is on the Board of Directors at Publicis Groupe SA, Morgan Stanley, K2 Intelligence, Inc., Merck Sharp & Dohme Corp., Merck & Co., Inc., MSD Pharma (Singapore) Pte Ltd., International Tennis Hall of Fame, Inc., K2 Integrity Holdings, Inc., K2 Intelligence LLC, System, Inc., The Atlantic Council of the United States, The International Business Council, Verto Analytics Oy, Verto Analytics, Inc. and The Cleveland Clinic Foundation. Mr. Glocer was previously employed as a Chief Executive Officer & Director by Thomson Reuters Corp., a Chief Executive Officer by Thomson Reuters Plc, a Vice President & Deputy Counsel by Reuters America Holdings, Inc., a Chief Executive Officer & Director by Reuters Group Plc, a Member-International Business Council by Forum Mondial de L'Economie, and a Non-Executive Director by Reynen Court LLC. He also served on the board at Adfin Solutions, Council on Foreign Relations, Inc. and The Partnership for New York City, Inc. He received his undergraduate degree from The Trustees of Columbia University in The City of New York and a graduate degree from Yale University.
旧服务已下线，请迁移至 http://api.fanyi.baidu.com
Patricia Fiorello Russo
Patricia Fiorello Russo is Independent Chairman at Hewlett Packard Enterprise Co. since 2015. Independent Director at Merck & Co., Inc. since 1995. Independent Director at KKR Management LLC since 2011. Lead Independent Director at General Motors Co. since 2021. Independent Director at KKR Group Co., Inc. since 2011. Director at Merck Sharp & Dohme Corp. since 1995. Director at Arconic Defense, Inc. Director at MSD Pharma (Singapore) Pte Ltd. since 1995. Independent Director at KKR & Co., Inc. since 2011. Member of The Conference Board, Inc. Member of The Economic Club of New York. Member of The Business Council. Former roles include Chairman & Chief Executive Officer at Lucent Technologies, Inc. from 2003 to 2006. Chief Executive Officer & Director at Nokia of America Corp. in 2008. Chief Executive Officer at Alcatel Lucent SA from 2006 to 2008. Chairman at Avaya LLC in 2002. Chairman at Partnership for Drug-Free Kids. Lead Independent Director at Arconic, Inc. in 2016. Lead Independent Director at HP, Inc. from 2014 to 2015. Director at Schering-Plough Corp. from 1995 to 2009. Director at Alcoa, Inc. from 1995 to 2009. Director at Arconic Corp. Lead Director at Motors Liquidation Co. Director at Alcoa Corp. Director at DXC Technology Co. Lead Independent Director at Howmet Aerospace, Inc. from 2017 to 2018. President & Chief Operating Officer at Eastman Kodak Co. in 2001. Trustee at Georgetown University. Education includes undergraduate degree from Georgetown University.
旧服务已下线，请迁移至 http://api.fanyi.baidu.com
Robert M. Davis
Robert M. Davis is currently the Chairman, President & Chief Executive Officer at Merck & Co., Inc. He is also the President, Chief Executive Officer & Director at MSD Pharma (Singapore) Pte Ltd. Additionally, he holds the position of Chairman at Gambro AB and serves as a Director at Catalyst, Inc., Duke Energy Corp., Project HOPE-The-People-To-People Health Foundation, Inc., and AdvaMedDx. In his former positions, Mr. Davis served as a Director at C. R. Bard, Inc. (New Jersey) from 2015 to 2017. He was the Director-Corporate Financial Planning at Eli Lilly & Co. from 1990 to 2004. From 2004 to 2010, he held the role of Chief Financial Officer & Vice President at Baxter Healthcare Corp. He then became the VP & President-Medical Products Business at Baxter International, Inc. from 2010 to 2014. He also served as a Trustee at Rush University Medical Center. Mr. Davis completed his undergraduate degree at Miami University. He obtained an MBA from Kellogg School of Management. He also holds a graduate degree from Northwestern University School of Law.
Pamela J. Craig
Pamela J. Craig currently works at The Committee of 200, as Vice Chairman from 2017, Corning, Inc., as Independent Director from 2021, Merck & Co., Inc., as Independent Director from 2015, Progressive Corp., as Independent Director from 2018, Smith College, as Director, Junior Achievement of New Jersey, Inc., as Director, Merck Sharp & Dohme Corp., as Director, Comprehensive Development, Inc., as Director from 2012, and MSD Pharma (Singapore) Pte Ltd., as Director from 2015. Ms. Craig also formerly worked at C200 Foundation, as Chairman, 3M Co., as Independent Director from 2019 to 2023, Walmart, Inc., as Independent Director from 2015 to 2017, Akamai Technologies, Inc., as Independent Director from 2011 to 2019, VMware LLC, as Independent Director from 2014 to 2015, Accenture Ltd., as Chief Financial Officer from 2001 to 2011, Accenture SCA, as Chief Financial Officer, Accenture Plc, as Chief Financial Officer from 2006 to 2013, Accenture LLP, as Chief Financial Officer from 2006 to 2013, and Avanade, Inc., as Chief Financial Officer from 2006 to 2009. Ms. Craig received her undergraduate degree from Smith College and Masters Business Admin degree from The Leonard N Stern School of Business.
Paul B. Rothman
Paul B. Rothman currently works at Laboratory Corporation of America Holdings, as Independent Director from 2023, Merck & Co., Inc., as Independent Director from 2015, Merck Sharp & Dohme Corp., as Director from 2015, King Faisal Specialist Hospital & Research Centre, as Director, MSD Pharma (Singapore) Pte Ltd., as Director from 2015, Center for Medical Interoperability, as Director from 2015, Labcorp Holdings, Inc., as Independent Director from 2024, The Johns Hopkins Hospital, Inc., as Ex-Officio Trustee, American Academy of Arts & Sciences, as Member, American Association for the Advancement of Science, as Member, National Academy of Medicine (United States), as Member, Association of American Physicians, as Member, American Society for Clinical Investigation, as Member, and Johns Hopkins Community Physicians, Inc., as Trustee. Dr. Rothman also formerly worked at Johns Hopkins Medicine, Inc., as Chief Executive Officer from 2012 to 2022, The Johns Hopkins Health System Corp., as Vice Chairman, Cancer Genetics, Inc., as Director in 2014, The Johns Hopkins University, as Vice President-Medicine from 2012 to 2022, and the University of Iowa Carver College of Medicine, as Dean from 2008 to 2012. Dr. Rothman received his undergraduate degree from Massachusetts Institute of Technology and doctorate degree from Yale University.
Inge G. Thulin
Inge G. Thulin is currently serving as the Vice Chairman at the United States Council for International Business and the Vice Chairman at The Kennedy Center Corporate Fund. He is also an Independent Director at Merck & Co., Inc., a Director at The Council for the United States & Italy, a Director at Merck Sharp & Dohme Corp., a Director at Patricia Industries AB, a Director at MSD Pharma (Singapore) Pte Ltd., and a Member of the Council on Foreign Relations, Inc., The Business Roundtable, The Business Council, The World Economic Forum USA, Inc., The International Business Council, and S llskapet. In his former positions, Mr. Thulin served as the Executive Chairman at 3M Co., an Independent Director at Chevron Corp., an Independent Director at The Toro Co., the Managing Director at 3M Russia ZAO, and held managerial roles at 3M Svenska AB and 3M Europe NV. He was also a Member of Forum Mondial de L'Economie. Mr. Thulin completed his undergraduate degree at the University of Gothenburg.
Mary Ellen Coe
Mary Ellen Coe is currently an Independent Director at Merck & Co., Inc., a Director at Merck Sharp & Dohme Corp., a Director at MSD Pharma (Singapore) Pte Ltd., the President-Global Customer Solutions at Google LLC, and the Chief Business Officer at YouTube, Inc. She previously served as an Independent Director at Whole Foods Market, Inc. Ms. Coe completed her undergraduate degree at the University of Michigan.
Kathy J. Warden
Kathy J. Warden is Chairman, President & Chief Executive Officer at Northrop Grumman Corp. since 2019. Vice Chairman at Greater Washington Partnership. Independent Director at Merck & Co., Inc. since 2020. Director at Catalyst, Inc. since 2019. Director at Wolf Trap Foundation for the Performing Arts. Director at Merck Sharp & Dohme Corp. since 2020. Director at MSD Pharma (Singapore) Pte Ltd. since 2020. Member of The Business Roundtable. Member of AFCEA International. Former Chairman of the Federal Reserve Bank of Richmond. Former Vice Chairman of the Aerospace Industries Association. Former Director-Global Services Operating Unit at General Electric Information Services. Former Senior Manager at GE Aerospace. Former Senior Vice President at Veridian Corp. Former President of Northrop Grumman Information Technology, Inc. Former Vice President & GM-Cyber Intelligence Division at Northrop Grumman Information Technology, Inc. Former President of Northrop Grumman Mission Systems. Former Vice President-Intelligence Systems at General Dynamics Advanced Information Systems, Inc. Former Member-Visitors Board at James Madison University. Education includes an MBA from George Washington University and an undergraduate degree from James Madison University.
Christine E. Seidman
Christine E. Seidman is the founder of MyoKardia, Inc. (2012). Dr. Seidman is currently an Independent Director at Merck & Co., Inc. (2020), Director-Cardiovascular Genetics Center at The Brigham & Women's Hospital, Inc. (1987), Director at The Burroughs Wellcome Fund, Director at Merck Sharp & Dohme Corp. (2020), Director at MSD Pharma (Singapore) Pte Ltd. (2020), Member of the National Academy of Sciences, Member of the American Academy of Arts & Sciences, Member of the National Academy of Medicine (United States), Member of the American Society for Clinical Investigation, Professor at Harvard Medical School (1997), Member of the Association of University Cardiologists, Scientific Advisory Board at BridgeBio Pharma, Inc., and Venture Partner at Catalio Capital Management LP. Dr. Seidman obtained an undergraduate degree from Harvard University and a doctorate from George Washington University.
Risa J. Lavizzo-Mourey
Currently, Risa J. Lavizzo-Mourey serves as Chairman-Regents Board at the Smithsonian Institution since 2014. Other current roles include Independent Director at Merck & Co., Inc. since 2020, Director at Princeton Medical Center, Director at Merck Sharp & Dohme Corp., Director at GE Healthcare, Inc. since 2023, Director at MSD Pharma (Singapore) Pte Ltd. since 2020, Independent Director at Better Therapeutics LLC since 2021, Trustee at Howard Hughes Medical Institute, Inc. since 2021, Member of the National Academy of Sciences, Member of the American Academy of Arts & Sciences, Member of the National Academy of Medicine (United States), Member of the American Philosophical Society, and Board of Advisors at Healthquest Capital Management Co LLC since 2022. Former positions include President Emerita & CEO of The Robert Wood Johnson Foundation; Co-Chairman at White House Health Care & Rehabilitation Center, Inc. from 1985 to 1998; Independent Director at Hess Corp. from 2004 to 2020; Independent Director at GE Aerospace from 2017 to 2023; Director at Hanger, Inc.; Director at Beckman Coulter, Inc. from 2001 to 2007; Independent Director at Genworth Financial, Inc. from 2007 to 2012; Director at Independent Sector; Director at Institute on Aging from 1994 to 2002; Independent Director at Better Therapeutics, Inc. from 2021 to 2024; Independent Director at Intel Corp. from 2018 to 2025; Professor at the University of Pennsylvania from 1986 to 2021; Trustee at Penn Medicine Princeton Health; Deputy Administrator at Agency for Healthcare Research & Quality from 1992 to 1994; Principal at Perelman School of Medicine from 1986 to 1992; Professor at the University of Pennsylvania Medical Center from 1995 to 2001. Education includes undergraduate studies at Stony Brook University, a doctorate from Harvard Medical School conferred in 1979, and an MBA from The Wharton School of the University of Pennsylvania conferred in 1986.
Stephen L. Mayo
Stephen L. Mayo is the founder of Xencor, Inc. (1997). Dr. Mayo is also the founder of Molecular Simulations, Inc.,Protabit LLC. Current jobs include Independent Director at Merck & Co., Inc. since 2021, Independent Director at Sarepta Therapeutics, Inc. since 2021, Director at MSD Pharma (Singapore) Pte Ltd. since 2021, Independent Director at Allogene Therapeutics, Inc. since 2022, and Professor at California Institute of Technology since 2020. Former jobs include Director at American Association for the Advancement of Science from 2010 to 2014 and Director at The National Science Foundation from 2013 to 2018. Education includes a doctorate from California Institute of Technology (1987) and an undergraduate degree from The Pennsylvania State University (1983).
Douglas M. Baker
Mr. Douglas M. Baker, Jr., is a Founding Partner at E2SG Partners LP, an Independent Director at Merck & Co., Inc., an Independent Director at Target Corp., a Chairman at ChampionX Holding, Inc. and a Member at Chief Executives For Corporate Purpose, Inc. He is on the Board of Directors at Merck & Co., Inc., Mayo Clinic, Target Corp., Minneapolis Saint Paul Regional Economic Development Partners, Minnesota Orchestral Association, Parent Aware For School Readiness, College of the Holy Cross (Massachusetts) and National Restaurant Association Educational Foundation. Mr. Baker was previously employed as an Independent Director by U.S. Bancorp and an Executive Chairman by Ecolab, Inc. He also served on the board at Nalco Holding Co. He received his undergraduate degree from the College of the Holy Cross (Massachusetts).
Surendralal Lanca Karsanbhai
Surendralal Lanca Karsanbhai currently works at Emerson Electric Co., as President, Chief Executive Officer & Director from 2021, Federal Reserve Bank of St. Louis, as Deputy Chairman, US-China Business Council, as Director, Merck & Co., Inc., as Director from 2025, The Business Roundtable, as Member, and Olin Business School, as Member. Mr. Karsanbhai received his graduate degree from Washington University in St. Louis and undergraduate degree from the University of Michigan.